Pubmed ID: 34902246
Publication Date: 2021/12/13

Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.

Hepatocyte growth factor (HGF), the ligand for the MET receptor tyrosine kinase, is a tumor-promoting factor that is abundant in the tumor microenvironment. Proteolytic activation of inactive pro-HGF by one or more of the serine endopeptidases matriptase, hepsin, and HGF activator is the rate-limiting step in HGF/MET signaling. Herein, we have rationally designed a novel class of side chain cyclized macrocyclic peptide inhibitors. The new series of cyclic tripeptides has superior metabolic stability and significantly improved pharmacokinetics in mice relative to the corresponding linear peptides. We identified the lead compound VD2173 that potently inhibits matriptase and hepsin, which was tested in parallel alongside the acyclic inhibitor ZFH7116 using both in vitro and in vivo models of lung cancer. We demonstrated that both compounds block pro-HGF activation, abrogate HGF-mediated wound healing, and overcome resistance to EGFR- and MET-targeted therapy in lung cancer models. Furthermore, VD2173 inhibited HGF-dependent growth of lung cancer tumors in mice.

Authors: Damalanka Vishnu C , Voss Jorine J L P , Mahoney Matthew W , Primeau Tina , Li Shunqiang , Klampfer Lidija , Janetka James W ,

Reference:

Related products :

Catalog number	Product name	Quantity
ATGP2037	Proteases & Inhibitors: MRI, 1-157aa, Human, His tag, E.coli	100ug
ATGP2037	Proteases & Inhibitors: MRI, 1-157aa, Human, His tag, E.coli	20ug
ATGP0764	Proteases & Inhibitors: BLMH, 1-455aa, Human, His tag, E.coli	100ug
ATGP2040	Proteases & Inhibitors: CST3, 27-146aa, Human, His tag, E.coli	50ug
ATGP2117	Proteases & Inhibitors: CST11, 26-103aa, Human, His tag, E.coli	0.5mg